Document text
Principal Investigator: Carey Lynn Shive
Organization: LOUIS STOKES CLEVELAND VA MEDICAL CENTER
Fiscal Year: 2022
Funding agency: Veterans Affairs
The global pandemic of SARS-CoV-2 is placing urgent demands on health care workers and researchers.
Between April 3rd and May 1st global cases of COVID19 nearly tripled from approximately 1 million to over 3
million. With the possibility of a reemergence of SARS-CoV-2 in the fall, rapid specific antibody assays are
essential. This application proposes to investigate the humoral immune responses to SARS-CoV-2 in veterans
and employees at the Cleveland VA Medical Center. The proposal has three aims. Aim 1) To develop rapid,
high throughput assays to measure total and functional antibodies to SARS-CoV-2 proteins in COVID19
infected individuals. In aim 1, we will establish a magnet bead-based assay that can detect antibody (Ab)
responses to up to 50 different epitopes of SARS-CoV-2 in one serum sample. This assay will also be able to
detect Abs that interfere with the binding of the receptor binding domain (RBD) of the spike protein of SARS-
CoV-2 to its receptor, ACE2. Antibodies that can block binding between the RBD and ACE2 on lung epithelial
cells will prevent viral entry and will likely be neutralizing. Aim 2) To determine if robust humoral immunity and
higher neutralizing Ab titers protect VA health care employees from clinical COVID19 compared to their
colleagues with low or no SAR2-CoV-2 specific antibodies. In aim 2 we will use a rapid antibody test to screen
Cleveland VA health care employees at high-risk for infection with COVID19 (first responders, emergency
department staff, intensive care unit staff, COVID19 ward staff). We will ask for a serum sample from those
that are Ab positive for COVID19 to examine the SARS-CoV-2 Ab response in more depth. We will examine
general Ab titers, neutralizing Ab titers, and antibody isotypes. If there is a resurgence of COVID19 in the fall,
we will determine if those health care employees with a robust humoral response are better protected from re-
infection than those employees who had a weak or no Ab response. Aim 3) To examine the association of
COVID19-induced lymphopenia with the ability to generate a humoral immune response. Older age, SARS-
CoV-1 and SARS-COV-2 infection are all associated with a decrease of white blood cells or lymphopenia. In
aim 3 we will examine the effect of lymphopenia on the development of the humoral Ab response to COVID19.
We expect that those individuals with severe lymphopenia will have few T follicular helper cells in their lymph
nodes and this will lead to poor Ab affinity maturation, isotype switching, and B cell memory development. In
summary, results from this project will provide a rapid SARS-CoV-2 specific serum assay able to detect
neutralizing Ab that can be used to screen VA healthcare workers for exposure to SARS-CoV-2. We will
investigate the humoral antibody responses of high-risk health care employees that were infected with
COVID19 and try to determine what constitutes protection from re-infection if there is a resurgence of
COVID19 in the fall. Lastly, we will gain an understanding of the B cell affinity maturation, isotype switching
and generation of B cell memory and neutralizing Ab titers and determine how lymphopenia may play a role in
the dysfunction of humoral immunity to COVID19. This knowledge will aid in development of better treatment
and future vaccines.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><4F9><ACE2><Accident and Emergency department><Acute Nasopharyngitis><Address><Affect><Affinity><Age><Antibodies><Antibody Affinity><Antibody Response><Antibody titer measurement><Antigenic Determinants><Antigens><Assay><Avidity><B blood cells><B cell><B cells><B-Cell Subsets><B-Cells><B-Lymphocyte Subsets><B-Lymphocytes><B-cell><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Blood Sample><Blood Serum><Blood leukocyte><Blood specimen><C33><CD82><CD82 Gene><COVID associated morbidity><COVID crisis><COVID epidemic><COVID induced morbidity><COVID morbidity><COVID pandemic><COVID related morbidity><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 associated death><COVID-19 associated fatality><COVID-19 associated morbidity><COVID-19 associated mortality><COVID-19 crisis><COVID-19 death><COVID-19 epidemic><COVID-19 exposure><COVID-19 fatality><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 induced death><COVID-19 induced fatality><COVID-19 induced morbidity><COVID-19 induced mortality><COVID-19 infection><COVID-19 morbidity><COVID-19 mortality><COVID-19 pandemic><COVID-19 positive><COVID-19 positivity><COVID-19 public health crisis><COVID-19 related death><COVID-19 related fatality><COVID-19 related morbidity><COVID-19 related mortality><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 S protein><COVID19 associated death><COVID19 associated fatality><COVID19 associated mortality><COVID19 crisis><COVID19 death><COVID19 epidemic><COVID19 fatality><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 induced death><COVID19 induced fatality><COVID19 induced mortality><COVID19 infection><COVID19 mortality><COVID19 pandemic><COVID19 positive><COVID19 positivity><COVID19 public health crisis><COVID19 related death><COVID19 related fatality><COVID19 related mortality><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Cell Body><Cells><Characteristics><Class Switching><Class Switchings><Clinic><Clinical><CoV-2><CoV2><Common Cold><Coronaviridae><Coronavirus><Development><Disease Progression><Dysfunction><ELISA><Elderly><Emergency Department><Emergency room><Employee><Enrollment><Enzyme-Linked Immunosorbent Assay><Epithelial Cells><Epitopes><Exposure to><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Foundations><Frequencies><Functional disorder><Future><GR15><Generations><Health Care Providers><Health Personnel><Healthcare><Healthcare Providers><Healthcare worker><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><High Throughput Assay><Hospitals><Humoral Immunities><IA4><Ig Somatic Hypermutation><Immune response><Immunochemical Immunologic><Immunoglobulin Class Switching><Immunoglobulin Class Switchings><Immunoglobulin Somatic Hypermutation><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Individual><Inducer Cells><Inducer T-Lymphocytes><Infection><Inpatients><Intensive Care Units><Investigators><Isotype Switching><Isotype Switchings><KAI1><KAI1 gene><Knowledge><Length><Leukocytes><Leukocytes Reticuloendothelial System><Lung><Lung Respiratory System><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Lymphocytopenia><Lymphopenia><Marrow leukocyte><Measures><Mediating><Medical center><Memory B Cell><Memory B-Lymphocyte><Molecular Interaction><Ohio><Out-patients><Outcome><Outpatients><Patients><Physiopathology><Play><Proteins><Receptor Protein><Recombinants><Research Personnel><Researchers><Risk><Role><SAR2><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 associated death><SARS-CoV-2 associated fatality><SARS-CoV-2 associated mortality><SARS-CoV-2 death><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 fatality><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 induced death><SARS-CoV-2 induced fatality><SARS-CoV-2 induced mortality><SARS-CoV-2 infection><SARS-CoV-2 mortality><SARS-CoV-2 pandemic><SARS-CoV-2 positive><SARS-CoV-2 positivity><SARS-CoV-2 related death><SARS-CoV-2 related fatality><SARS-CoV-2 related mortality><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><ST6><Sampling><Seroprevalences><Serum><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Severity of illness><T-Cells><T-Lymphocyte><Testing><Vaccines><Veterans><Viral><Virus><White Blood Cells><White Cell><Wuhan coronavirus><advanced age><ages><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody assay><antibody based detection><antibody based test><antibody detection><antibody test><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody-based immunity><antigen antibody affinity><antigen based detection><antigen detection><base><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 associated death><coronavirus disease 2019 associated fatality><coronavirus disease 2019 associated morbidity><coronavirus disease 2019 associated mortality><coronavirus disease 2019 crisis><coronavirus disease 2019 death><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 fatality><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 induced death><coronavirus disease 2019 induced fatality><coronavirus disease 2019 induced morbidity><coronavirus disease 2019 induced mortality><coronavirus disease 2019 infection><coronavirus disease 2019 morbidity><coronavirus disease 2019 mortality><coronavirus disease 2019 pandemic><coronavirus disease 2019 positive><coronavirus disease 2019 positivity><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related death><coronavirus disease 2019 related fatality><coronavirus disease 2019 related morbidity><coronavirus disease 2019 related mortality><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease associated morbidity><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced morbidity><coronavirus disease morbidity><coronavirus disease pandemic><coronavirus disease related morbidity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 mortality><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><death due to COVID-19><death due to COVID19><death due to SARS-CoV-2><death due to coronavirus disease 2019><death due to severe acute respiratory syndrome coronavirus 2><death in COVID><death in COVID-19><death in SARS-CoV-2><death in coronavirus disease><death in coronavirus disease 2019><death in severe acute respiratory syndrome coronavirus 2><detect antibodies><detect antigen><develop a vaccine><develop therapy><develop vaccines><development of a vaccine><developmental><disease severity><elders><enroll><enzyme linked immunoassay><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><falls><fatality due to COVID-19><fatality due to COVID19><fatality due to SARS-CoV-2><fatality due to coronavirus disease 2019><fatality due to severe acute respiratory syndrome coronavirus 2><first responder><flow cytophotometry><geriatric><hCoV19><health care><health care personnel><health care worker><health provider><health workforce><healthcare personnel><high risk><high throughput screening><host response><immune system response><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunogen><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection risk><intervention development><late life><later life><lymph gland><lymph nodes><lymphnodes><medical personnel><mortality due to COVID-19><mortality due to COVID19><mortality due to SARS-CoV-2><mortality due to coronavirus disease 2019><mortality due to severe acute respiratory syndrome coronavirus 2><nCoV2><neutralizing antibody><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapeutics><novel therapy><older adult><older person><pandemic><pandemic disease><pathophysiology><prevent><preventing><pulmonary><receptor><receptor binding><receptor bound><respiratory><response><senior citizen><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 associated death><severe acute respiratory syndrome coronavirus 2 associated fatality><severe acute respiratory syndrome coronavirus 2 associated mortality><severe acute respiratory syndrome coronavirus 2 death><severe acute respiratory syndrome coronavirus 2 fatality><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced death><severe acute respiratory syndrome coronavirus 2 induced fatality><severe acute respiratory syndrome coronavirus 2 induced mortality><severe acute respiratory syndrome coronavirus 2 mortality><severe acute respiratory syndrome coronavirus 2 related death><severe acute respiratory syndrome coronavirus 2 related fatality><severe acute respiratory syndrome coronavirus 2 related mortality><severe acute respiratory syndrome-CoV><social role><somatic hypermutation><symptomatic COVID-19><symptomatic COVID19><symptomatic coronavirus disease 2019><therapeutic agent development><therapeutic development><therapy development><thymus derived lymphocyte><treatment development><treatment provider><vaccine development><ward><white blood cell><white blood corpuscle>